Huonslab

메뉴 바로가기: 주메뉴 바로가기; 컨텐츠 바로가기

IR

Huonslab in the News

Announcement [게시판]

Download

Huonslab Participates in ‘BIO CHINA 2026’, Drawing Attention from Biotechnology Companies - Showcased HyDIFFUZE™ based formulation conversion technology and stand-alone drug product, HYDIZYME™ -

Huonslab Announces Applicable SC delivery for Antibodies and ADCs with “HyDIFFUZE™ Platform”

Huonslab on Track for Recombinant Human Hyaluronidase ‘HYDIZYME™ Injection’ Development

Huonslab has submitted the Biologics License Application for Recombinant Human Hyaluronidase ‘HYDIZYME™ Injection’ - Applying HyDIFFUZE™ technology… Aiming for Approval in 2026 -

Huonslab Secures Formulation Patent for Recombinant Human Hyaluronidase Product, HYDIZYME™

Huonslab presents its remarkable formulation conversion technology at BIO USA

Huonslab Achieves ‘Last-Patient-In (LPI)’ in Phase 1 Pivotal Study for Recombinant Human Natural Hyaluronidase PH20 (rHuPH20)

Huonslab Announced the Results of HLB3-002 Formulation Conversion Study in a Poster Presentation at 2025 AACR

Huonslab Announces Positive Results from Non-Clinical PK Comparative Study of Trastuzumab Co-formulated with HyDIFFUZE™

Huonslab Receives IND Approval from MFDS to Start Pivotal Clinical Trial for ‘Recombinant Human